Showing results (11-20 of 29) with videos related to

Sort By:
Pageof 3
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 1, 2008
BRCA1 p.Val1688del is a deleterious mutation that recurs in breast and ovarian cancer families from Northeast ItalySandro Malacrida, Simona Agata, Monia Callegaro, et al.
Genetics in Medicine : Official Journal of the American College of Medical Genetics|January 18, 2011
Integrated analysis of unclassified variants in mismatch repair genesChiara Pastrello, Elisa Pin, Fabio Marroni, et al.
International Journal of Cancer|August 7, 2012
MUTYH c.933+3A>C, associated with a severely impaired gene expression, is the first Italian founder mutation in MUTYH-Associated PolyposisElisa Pin, Chiara Pastrello, Rossella Tricarico, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|January 28, 2021
Definition and management of colorectal polyposis not associated with APC/MUTYH germline pathogenic variants: AIFEG consensus statementEmanuele Damiano Luca Urso, Maurizio Ponz de Leon, Marco Vitellaro, et al.
The Lancet. Oncology|June 1, 2005
Gemcitabine versus cisplatin, epirubicin, fluorouracil, and gemcitabine in advanced pancreatic cancer: a randomised controlled multicentre phase III trialMichele Reni, Stefano Cordio, Carlo Milandri, et al.
Pharmacology Research & Perspectives|August 20, 2020
Predicting steady-state endoxifen plasma concentrations in breast cancer patients by CYP2D6 genotyping or phenotyping. Which approach is more reliable?Milena Gusella, Felice Pasini, Barbara Corso, et al.
The Oncologist|November 15, 2017
First Prospective Multicenter Italian Study on the Impact of the 21-Gene Recurrence Score in Adjuvant Clinical Decisions for Patients with ER Positive/HER2 Negative Breast CancerMaria Vittoria Dieci, Valentina Guarneri, Tommaso Giarratano, et al.
The Oncologist|June 2, 2019
Impact of 21-Gene Breast Cancer Assay on Treatment Decision for Patients with T1-T3, N0-N1, Estrogen Receptor-Positive/Human Epidermal Growth Receptor 2-Negative Breast Cancer: Final Results of the Prospective Multicenter ROXANE StudyMaria Vittoria Dieci, Valentina Guarneri, Fable Zustovich, et al.
Genes, Chromosomes & Cancer|June 9, 2005
Molecular characterization of the spectrum of genomic deletions in the mismatch repair genes MSH2, MLH1, MSH6, and PMS2 responsible for hereditary nonpolyposis colorectal cancer (HNPCC)Heleen van der Klift, Juul Wijnen, Anja Wagner, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 3, 2005
Microsatellite instability and colorectal cancer prognosisPiero Benatti, Roberta Gafà, Daniela Barana, et al.
Pageof 3